This cross-sectional study reports trends in glucagon-like peptide-1 (GLP-1) prescriptions for plans that do and do not cover GLP-1s for weight loss.
Share your take
Add a clinician perspective alongside expert commentary.
Shahzad et al. (2026) studied this question.